

Crohn's and Ulcerative Colitis Referral Form	Y Medical Associates Fax : 855-838-0623 Phone: 800-447-7558			
Date: _____				
Patient Information		Prescriber Information		
Please complete the following or send patient demographic sheet		Prescriber Name: _____		
Patient Name: _____		Address: _____		
Address: _____		City, State, Zip: _____		
City, State, Zip: _____		Phone: _____ Fax: _____		
Home Phone: _____		DEA: _____ NPI #: _____		
Cell Phone: _____		Contact Person: _____		
DOB: _____ Gender: <input type="checkbox"/> M <input type="checkbox"/> F				
Insurance Information				
Primary Insurance: _____ ID#: _____ Group: _____				
Secondary Insurance: _____ ID#: _____ Group: _____				
Prescription Card: _____ ID#: _____ BIN#: _____ PCN#: _____ Group: _____				
Medical Information (Section must be completed to process prescription) (Attach separate sheet if needed)				
Prior Authorization Insurance Number: _____				
Diagnosis - Please include diagnosis name with ICD-10 code		Therapy Details: <input type="checkbox"/> New <input type="checkbox"/> Reauthorization <input type="checkbox"/> Restart		
<input type="checkbox"/> K50.00 Crohn's disease of small intestines without complications <input type="checkbox"/> K50.8 Crohn's disease of both intestines without complications <input type="checkbox"/> K50.10 Crohn's disease of large intestines without complications <input type="checkbox"/> K50.90 Crohn's disease, unspecified, without complications <input type="checkbox"/> K20.0 Eosinophilic Esophagitis <input type="checkbox"/> Other diagnosis: ICD-10 code _____		Weight _____ kg/lbs Height _____ cm/in		
Description _____ Date of Description _____		Allergies _____		
Has a TB test been performed? <input type="checkbox"/> Yes <input type="checkbox"/> No		Lab Data _____		
Does the Patient have an active infection? <input type="checkbox"/> Yes <input type="checkbox"/> No		Prior Therapies _____		
Start Date _____ Review Date _____		Concomitant Medications _____		
		Additional Comments _____		
		Injection Training Required? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Prescription Information				
Medication	Dose Strength	Directions	Qty	Refills
<input type="checkbox"/> Cimzia	<input type="checkbox"/> 200mg/mL Vial Kit <input type="checkbox"/> 200 mg/mL Starter Ki <input type="checkbox"/> 200mg/mL prefilled Syringe	<input type="checkbox"/> Loading Dose: Inject 400mg SUBQ at Weeks 0, 2, and 4 <input type="checkbox"/> Maintenance Dose: Inject 200mg SUBQ every 2 weeks		
<input type="checkbox"/> Dupixent	<input type="checkbox"/> PFS with needle shield 300 mg/2 mL <input type="checkbox"/> Prefilled Pen 300 mg/2 mL	<input type="checkbox"/> Inject 300 mg SUBQ every week		
<input type="checkbox"/> Entyvio	<input type="checkbox"/> 300mg vial	<input type="checkbox"/> Loading Dose: Inject 300mg IV over 30 minutes at Weeks 0, 2, and 6. <input type="checkbox"/> Maintenance Dose: Infuse 300mg IV over 30 minutes every 8 weeks		
<input type="checkbox"/> Humira <input type="checkbox"/> Adalimumab (biosimilar)	Starter Kits: <input type="checkbox"/> 80mg/0.8mL Starter Pack Pre-Filled Pen (Citrate Free) Maintenance: <input type="checkbox"/> 40mg/0.4mL Pre-Filled Pen (Citrate Free) <input type="checkbox"/> 40mg/0.4mL Pre-Filled Syringe (Citrate Free) <input type="checkbox"/> Other: _____	Adult: <input type="checkbox"/> Loading Dose: Inject 160mg SUBQ on Day 1, then 80mg on Day 15 (two weeks later) <input type="checkbox"/> Maintenance Dose: Inject 40mg SUBQ every other week (starting Day 29) Pediatric (>6 years and adolescents) 17kg to < 40kg <input type="checkbox"/> Loading Dose: Inject 80mg SUBQ on Day 1, 40mg on Day 15 (two weeks later) <input type="checkbox"/> Maintenance Dose: Inject 20mg SUBQ every other week (starting Day 29) Pediatric (>6 years and adolescents) > 40kg <input type="checkbox"/> Loading Dose: Inject 160mg SUBQ on Day 1, 80mg on Day 15 (two weeks later) <input type="checkbox"/> Maintenance Dose: Inject 40mg SUBQ every other week (starting Day 29)		
Prescriber Signature: _____ DAW (Dispense as Written) <input type="checkbox"/> Y <input type="checkbox"/> N Date: _____				

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intended recipient, please notify us immediately by calling or faxing back to the originator.

Crohn's and Ulcerative Colitis Referral Form

Y Medical Associates
Fax : 855-838-0623
Phone: 800-447-7558



Date: _____

Patient Information

Please complete the following or send patient demographic sheet

Patient Name: _____
 Address: _____
 City, State, Zip: _____
 Home Phone: _____
 Cell Phone: _____
 DOB: _____ Gender: M F

Prescriber Information

Prescriber Name: _____
 Address: _____ City, _____
 State, Zip: _____
 Phone: _____
 Fax: _____
 DEA: _____ NPI #: _____
 Contact Person: _____

Insurance Information

Primary Insurance: _____ ID#: _____ Group: _____
 Secondary Insurance: _____ ID#: _____ Group: _____
 Prescription Card: _____ ID#: _____ BIN#: _____ PCN#: _____ Group: _____

Medical Information (Section must be completed to process prescription)

(Attach separate sheet if needed)

Prior Authorization Insurance Number: _____

Diagnosis - Please include diagnosis name with ICD-10 code

- K50.00 Crohn's disease of small intestines without complications
- K50.8 Crohn's disease of both intestines without complications
- K50.10 Crohn's disease of large intestines without complications
- K50.00 Crohn's disease, unspecified, without complications

Other diagnosis: ICD-10 code _____
 Description _____ Date of Description _____
 Has a TB test been performed? Yes No
 Does the Patient have an active infection? Yes No
 Start Date _____ Review Date _____

Therapy Details: New Reauthorization Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____ Lab _____
 Data _____ Prior _____
 Therapies _____
 Concomitant Medications _____
 Additional Comments _____
 Injection Training Required? Yes No

Prescription Information

Medication	Dose Strength	Directions	Qty	Refills
<input type="checkbox"/> Avsola <input type="checkbox"/> Inflectra <input type="checkbox"/> Remicade <input type="checkbox"/> Renflexis	<input type="checkbox"/> 100mg Vial	<input type="checkbox"/> Loading Dose: Infuse 5mg/kg at Weeks 0, 2, and 6 <input type="checkbox"/> Maintenance Dose: Infuse 5mg/kg every 8 weeks		
<input type="checkbox"/> Rinvoq	<input type="checkbox"/> Induction Therapy – 45 mg tablet <input type="checkbox"/> Maintenance Therapy – 15 mg or 30 mg tablets	<input type="checkbox"/> Induction Therapy: 45 mg PO daily x 8 weeks. Maintenance Therapy: <input type="checkbox"/> 15 mg PO daily <input type="checkbox"/> 30 mg PO daily		
<input type="checkbox"/> Simponi	<input type="checkbox"/> 100mg/mL Smart Ject Auto Injector <input type="checkbox"/> 100mg/mL Prefilled Syringe	<input type="checkbox"/> Loading Dose: Inject 200 mg SUBQ at Week 0 then 100mg at Week 2 <input type="checkbox"/> Maintenance Dose: Inject 100mg SUBQ every 4 weeks		
<input type="checkbox"/> Stelara	<input type="checkbox"/> 130mg/26mL solution single dose vial <input type="checkbox"/> 90mg/mL Prefilled Syringe Date of Initial Infusion: _____	<input type="checkbox"/> Loading Dose: Infuse: <input type="checkbox"/> 260mg <input type="checkbox"/> 390mg <input type="checkbox"/> 520mg as initial IV dose as directed by prescriber <input type="checkbox"/> Maintenance Dose: Inject 90mg SUBQ every 8 weeks (begin dosing 8 weeks after the IV induction dose)		
<input type="checkbox"/> Skyrizi	<input type="checkbox"/> Initiation Therapy – 600 mg/10 mL single use vial. Ongoing Therapy: <input type="checkbox"/> 180 mg/1.2 mL prefilled cartridge with On-Body Injector <input type="checkbox"/> 360 mg/2.4 mL prefilled cartridge with On-Body Injector	<input type="checkbox"/> Initiation Therapy – Inject 600mg IV over at least 1 hour at Weeks 0, 4, 8, 1 vial/week. <input type="checkbox"/> Ongoing Therapy – Week 12 - Inject 180mg or 360mg SUBQ and every 8 weeks thereafter. 1 device with prefilled cartridge.		
<input type="checkbox"/> Tremfya	Subcutaneous Injection: <input type="checkbox"/> 100 mg/mL in a single-dose One-Press patient-controlled injector <input type="checkbox"/> 200 mg/2 mL in a single-dose prefilled pen (Tremfya Pen) <input type="checkbox"/> 100 mg/mL in a single-dose prefilled syringe <input type="checkbox"/> 200 mg/2 mL in a single-dose prefilled syringe Intravenous Infusion: <input type="checkbox"/> 200 mg/20 mL (10 mg/mL) solution in a single-dose vial	Induction: <input type="checkbox"/> 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, Week 8 Maintenance: <input type="checkbox"/> 100 mg administered by subcutaneous injection at Week 16, and every 8 Week thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 Weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic response.		
<input type="checkbox"/> Xeljanz	<input type="checkbox"/> 5mg tablet <input type="checkbox"/> 10mg tablet <input type="checkbox"/> 11mg XR tablet <input type="checkbox"/> 22mg XR tablet	<input type="checkbox"/> Loading Dose: <input type="checkbox"/> 10mg twice daily for 8 weeks <input type="checkbox"/> XR: 22mg once for 8 weeks <input type="checkbox"/> Maintenance Dose: <input type="checkbox"/> 5mg twice daily <input type="checkbox"/> XR: 11mg once daily <input type="checkbox"/> 10mg twice daily <input type="checkbox"/> XR: 22mg once daily		

Prescriber Signature: _____ DAW (Dispense as Written) Y N Date: _____

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intend recipient, please notify us immediately by calling or faxing back to the originator.